OKYO Pharma Ltd - New
Research OKYO Pharma Ltd - New (OKYO) on Bullrun: market cap USD 79.77M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerOKYO
- ExchangeNASDAQ
- CountryUnited Kingdom
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 79.77M
- Financial periodQ3 2025
- Net income-USD 4.61M
- Free cash flow-USD 3.10M
Valuation Snapshot
latest market cap is USD 79.77M.
About OKYO Pharma Ltd - New
OKYO Pharma Limited, a clinical-stage biopharmaceutical company, develops therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase II clinical trials for the treatment of dry eye disease; in Phase II clinical trial to treat neuropathic corneal pain; and is in preclinical trial to treat allergic conjunctivitis and uveitis.
Frequently asked questions
What is OKYO Pharma Ltd - New's market cap?
OKYO Pharma Ltd - New's market capitalization is USD 79.77M.
What does OKYO Pharma Ltd - New do?
OKYO Pharma Limited, a clinical-stage biopharmaceutical company, develops therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom.